Atypical Hemolytic‐Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment

• Published in: Therapeutic apheresis and dialysis Vol. 23; no. 1; pp. 4 - 21
• Main Authors: Raina, Rupesh, Krishnappa, Vinod, Blaha, Taryn, Kann, Taylor, Hein, William, Burke, Linda, Bagga, Arvind
• Format: Journal Article
• Language: English
• Published: Kyoto, Japan John Wiley & Sons Australia, Ltd 01-02-2019
• Subjects: Atypical hemolytic uremic syndrome; Complement regulatory protein mutation; Eculizumab; Renal impairment; Thrombotic microangiopathy; Atypical hemolytic uremic syndrome; Eculizumab; Thrombotic microangiopathy; Complement regulatory protein mutation; Renal impairment
• ISSN: 1744-9979; 1744-9987
• DOI: 10.1111/1744-9987.12763

Atypical hemolytic uremic syndrome (aHUS), a rare variant of thrombotic microangiopathy, is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and renal impairment. The condition is associated with poor clinical outcomes with high morbidity and mortality. Atypical HUS predominantly affects the kidneys but has the potential to cause multi‐organ system dysfunction. This uncommon disorder is caused by a genetic abnormality in the complement alternative pathway resulting in over‐activation of the complement system and formation of microvascular thrombi. Abnormalities of the complement pathway may be in the form of mutations in key complement genes or autoantibodies against specific complement factors. We discuss the pathophysiology, clinical manifestations, diagnosis, complications, and management of aHUS. We also review the efficacy and safety of the novel therapeutic agent, eculizumab, in aHUS, pregnancy‐associated aHUS, and aHUS in renal transplant patients.